invoX Pharma CEO Ben Toogood (L) and F-star CEO Eliot Forster
F-star bought out in $161M all-cash deal as Hong Kong's Sino Biopharm looks toward international expansion
After more than a decade and a half of charting its own course, F-star Therapeutics will now settle under a new umbrella company.
The UK …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
